Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide

被引：5

作者：

Eclache, Virginie ^{[1
]}

Da Rocha, Anna ^{[1
]}

Le Roux, Genevieve ^{[1
]}

Fenaux, Pierre ^{[1
]}

机构：

[1] Univ Paris XIII, Hop Avicenne, AP HP, Serv Hematol Clin & Biol, 125 Rue Stalingrad, F-93000 Bobigny, France

来源：

HAEMATOLOGICA | 2008年 / 93卷 / 02期

关键词：

lenalidomide; myelodysplastic syndromes; del(5q) MDS; transfusion-dependent; case study;

D O I：

10.3324/haematol.11917

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lenalidomide is a very active drug in myelodysplastic syndrome with del (5q). We report such a patient treated with this drug who developed unusual complex cytogenetic abnormalities, which were elucidated by multi-FISH and FISH analysis as jumping translocations involving the long arm of chromosome 5, that resulted in an increase of 5q copies. This unusual findings is discussed in the context of resistance to lenalidomide observed in this patient.

引用

收藏

页码：315 / 316

页数：2

相关论文

共 10 条

[1] Jumping translocation in acute leukemia of myelomonocytic lineage:: a case report and review of the literature [J].

Bernard, M ;

Lemée, F ;

Picard, F ;

Ghandour, C ;

Drenou, B ;

Le Prise, PY ;

Lamy, T .

LEUKEMIA, 2000, 14 (01) :119-122

[2] Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro [J].

Dredge, K ;

Horsfall, R ;

Robinson, SP ;

Zhang, LH ;

Lu, L ;

Tang, Y ;

Shirley, MA ;

Muller, G ;

Schafer, P ;

Stirling, D ;

Dalgleish, AG ;

Bartlett, JB .

MICROVASCULAR RESEARCH, 2005, 69 (1-2) :56-63

[3] Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 [J].

Giagounidis, AAN ;

Germing, U ;

Haase, S ;

Hildebrandt, B ;

Schlegelberger, B ;

Schoch, C ;

Wilkens, L ;

Heinsch, M ;

Willems, H ;

Aivado, M ;

Aul, C .

LEUKEMIA, 2004, 18 (01) :113-119

[4] Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy [J].

Hochhaus, A ;

Kreil, S ;

Corbin, AS ;

La Rosée, P ;

Müller, MC ;

Lahaye, T ;

Hanfstein, B ;

Schoch, C ;

Cross, N ;

Berger, U ;

Gschaidmeier, H ;

Druker, BJ ;

Hehlmann, R .

LEUKEMIA, 2002, 16 (11) :2190-2196

[5] Interstitial telomere repeats in translocations of hematopoietic disorders [J].

Le Coniat, MB ;

Brizard, F ;

Smadja, NV ;

Maarek, O ;

Der Sarkissian, H ;

Berger, R .

LEUKEMIA, 2000, 14 (09) :1630-1633

[6] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion [J].

List, Alan ;

Dewald, Gordon ;

Bennett, John ;

Giagounidis, Aristotle ;

Raza, Azra ;

Feldman, Eric ;

Powell, Bayard ;

Greenberg, Peter ;

Thomas, Deborah ;

Stone, Richard ;

Reeder, Craig ;

Wride, Kenton ;

Patin, John ;

Schmidt, Michele ;

Zeldis, Jerome ;

Knight, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1456-1465

[7]

NAJFELD V, 1995, LEUKEMIA, V9, P634

[8] Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients [J].

Pellagatti, Andrea ;

Jaedersten, Martin ;

Forsblom, Ann-Mari ;

Cattan, Helen ;

Christensson, Birger ;

Emanuelsson, Emma K. ;

Merup, Mats ;

Nilsson, Lars ;

Samuelsson, Jan ;

Sander, Birgitta ;

Wainscoat, James S. ;

Boultwood, Jacqueline ;

Helistroem-Lindberg, Eva .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (27) :11406-11411

[9] DISTINCT HEMATOLOGICAL DISORDER WITH DELETION OF LONG ARM OF NO 5 CHROMOSOME [J].

VANDENBERGHE, H ;

CASSIMAN, JJ ;

DAVID, G ;

FRYNS, JP ;

MICHAUX, JL ;

SOKAL, G .

NATURE, 1974, 251 (5474) :437-438

[10] Pathogenesis of jumping translocations: a molecular cytogenetics study [J].

Wan, TSK ;

Ma, SK ;

Chow, EYD ;

Li, YH ;

Lin, SY ;

Chan, LC .

LEUKEMIA RESEARCH, 2004, 28 (10) :1075-1079